Literature DB >> 2562914

Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.

L H Price1, G A Ricaurte, J H Krystal, G R Heninger.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in laboratory animals. To assess its effects on 5-HT function in humans, serum prolactin (PRL) and mood responses to intravenous L-tryptophan were measured in nine recreational users of MDMA and compared with findings from nine matched healthy controls. L-Tryptophan induced a rise in the PRL concentration in controls, but not in MDMA users. Peak change and the area under the curve of the PRL response appeared to be blunted in MDMA users, but the difference from controls did not reach statistical significance. This study provides suggestive evidence of altered 5-HT function in MDMA users, but more definitive studies clearly are needed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562914     DOI: 10.1001/archpsyc.1989.01810010022003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  Chronic paranoid psychosis after misuse of MDMA ("ecstasy")

Authors:  P McGuire; T Fahy
Journal:  BMJ       Date:  1991-03-23

Review 2.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 3.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine.

Authors:  D Zhou; M Schreinert; J Pilz; G Huether
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 6.  Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.

Authors:  Jean Lud Cadet; Irina N Krasnova; Subramaniam Jayanthi; Johnalyn Lyles
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

7.  Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs.

Authors:  P G Jorens; L Heytens; H E Demey; S Andries; G A Ricaurte; L Bossaert; P J Schepens
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

Review 8.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

Review 9.  3,4-methylenedioxymethamphetamine (MDMA): a review.

Authors:  G O'Leary; J Nargiso; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

10.  Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory.

Authors:  K P C Kuypers; R de la Torre; M Farre; M Pujadas; J G Ramaekers
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.